Helus Pharma (STU:R7E) Total Operating Expense: €122.56 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:R7E Helus Pharma Inc STU:R7E
38 GF Score
Price €6.39
! 2 Warning Signs
View Full Analysis

What is Helus Pharma Total Operating Expense?

Helus Pharma STU:R7E +2.73% 38 Total Operating Expense is €122.56 Mil as of Mar. 2026. GuruFocus rates STU:R7E with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Helus Pharma's Total Operating Expense for the three months ended in Mar. 2026 was €41.40 Mil. Helus Pharma's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €122.56 Mil.

Helus Pharma Total Operating Expense Related Terms

Helus Pharma Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Helus Pharma's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma Total Operating Expense Chart

Helus Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial 46.43 35.57 53.68 95.39 123.34

Helus Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.44 21.35 24.62 35.19 41.40
STU:R7E
38GF Score
Helus Pharma Inc STU:R7E
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helus Pharma Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €122.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €122.56 Mil mean?
Helus Pharma (STU:R7E) has a Total Operating Expense of €122.56 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Helus Pharma and its competitors.
Is Helus Pharma's Total Operating Expense too high?
Helus Pharma's current Total Operating Expense is €122.56 Mil. Overall, Helus Pharma has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Total Operating Expense compare to VRTX and REGN?
Helus Pharma's Total Operating Expense of €122.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Helus Pharma and its competitors. Helus Pharma's current Total Operating Expense is €122.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (STU:R7E) has a current Total Operating Expense of €122.56 Mil. The current Total Operating Expense is €122.56 Mil. Helus Pharma's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Helus Pharma (STU:R7E), the current Total Operating Expense is €122.56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges HELP:USAHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
38GF Score

Get the complete analysis for STU:R7E

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.39
Price